Prime Medicine, Inc. Payments to Acquire Short-term Investments
Prime Medicine, Inc. (PRME) reported Payments to Acquire Short-term Investments of $26.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-06
- Prime Medicine, Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $18.99M, a 174.92% increase year-over-year.
- Prime Medicine, Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $7.28M, a 84.93% decline year-over-year.
- Prime Medicine, Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $15.88M.
- Prime Medicine, Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $134.31M, a 1190.78% increase year-over-year.
- Prime Medicine, Inc. payments to acquire short-term investments for fiscal 2025 was $205.41M, a 58.68% increase from fiscal 2024.
- Prime Medicine, Inc. payments to acquire short-term investments for fiscal 2024 was $129.45M, a 23.34% increase from fiscal 2023.
- Prime Medicine, Inc. payments to acquire short-term investments for fiscal 2023 was $104.95M, a 14.91% decline from fiscal 2022.
- Prime Medicine, Inc. payments to acquire short-term investments for fiscal 2022 was $123.34M, a 50.45% increase from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $26.27M 10-Q · filed 2026-08-06 | $42.15M derived: sum of 3 quarters · filed 2026-08-06 | $176.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.28M 10-Q · filed 2026-05-07 | $23.16M derived: sum of 2 quarters · filed 2026-05-07 | $157.47M derived: sum of 3 quarters · filed 2026-05-07 | $164.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $150.19M derived: sum of 2 quarters · filed 2026-03-03 | $157.09M derived: sum of 3 quarters · filed 2026-08-06 | $205.41M 10-K · filed 2026-03-03 |
| 2025-09-30 | $134.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $141.21M derived: sum of 2 quarters · filed 2026-08-06 | $189.53M 10-Q · filed 2025-11-07 | $172.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $55.23M 10-Q · filed 2026-08-06 | $38.36M derived: sum of 3 quarters · filed 2026-08-06 | $48.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $48.32M 10-Q · filed 2026-05-07 | $31.45M derived: sum of 2 quarters · filed 2026-05-07 | $41.86M derived: sum of 3 quarters · filed 2026-05-07 | $70.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$16.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$6.46M derived: sum of 2 quarters · filed 2026-03-03 | $22.24M derived: sum of 3 quarters · filed 2026-03-03 | $129.45M 10-K · filed 2026-03-03 |
| 2024-09-30 | $10.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $39.11M derived: sum of 2 quarters · filed 2025-11-07 | $146.32M 10-Q · filed 2025-11-07 | $150.73M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $28.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $135.91M 10-Q · filed 2025-08-07 | $140.32M derived: sum of 3 quarters · filed 2025-08-07 | $195.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $107.21M 10-Q · filed 2025-05-08 | $111.62M derived: sum of 2 quarters · filed 2025-05-08 | $166.50M derived: sum of 3 quarters · filed 2025-05-08 | $166.49M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $59.29M derived: sum of 2 quarters · filed 2025-02-28 | $59.28M derived: sum of 3 quarters · filed 2025-02-28 | $104.95M 10-K · filed 2025-02-28 |
| 2023-09-30 | $54.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $54.88M derived: sum of 2 quarters · filed 2024-11-12 | $100.54M 10-Q · filed 2024-11-12 | $134.41M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $45.66M 10-Q · filed 2024-08-08 | $79.53M derived: sum of 3 quarters · filed 2024-08-08 | $94.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $45.67M 10-Q · filed 2024-05-10 | $79.54M derived: sum of 2 quarters · filed 2024-05-10 | $94.26M derived: sum of 3 quarters · filed 2024-05-10 | $169.00M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $33.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $48.59M derived: sum of 2 quarters · filed 2024-03-01 | $123.34M derived: sum of 3 quarters · filed 2024-03-01 | $123.34M 10-K · filed 2024-03-01 |
| 2022-09-30 | $14.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $89.46M derived: sum of 2 quarters · filed 2023-11-03 | $89.46M 10-Q · filed 2023-11-03 | $89.60M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $74.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $74.74M 10-Q · filed 2023-08-07 | $74.88M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $139.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $81.98M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $81.84M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |